Listen
AROMASIN
-
Opinions on drugs -
Posted on
Jul 19 2006
- Updated on
Apr 16 2008
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication
-
Clinical Benefit
| Substantial |
The actual benefit of Aromasin is substantial. |
Clinical Added Value
| moderate |
According to the IES trial results, sequential therapy [tamoxifen followed by Aromasin (exemestane)] compared to tamoxifen provides a moderate improvement in actual benefit (IAB level III) in terms of efficacy when adjuvant hormone therapy is prescribed for 5 years to postmenopausal women with oestrogen receptor positive early breast cancer. Its prescription is therefore justified in patients who have received adjuvant therapy with tamoxifen for 2–3 years. |
Contact Us
Évaluation des médicaments
